Bioventus (NASDAQ:BVS) Shares Up 5.1% – Should You Buy?

Bioventus Inc. (NASDAQ:BVS) shares traded up 5.1% on Wednesday . The stock traded as high as $8.59 and last traded at $8.52. 291,690 shares traded hands during trading, a decline of 31% from the average session volume of 423,999 shares. The stock had previously closed at $8.11.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a research report on Wednesday, March 4th. CJS Securities assumed coverage on shares of Bioventus in a research report on Friday, March 27th. They set a “market outperform” rating and a $14.00 price target for the company. Barrington Research reissued an “outperform” rating and set a $14.00 price target on shares of Bioventus in a research report on Friday, May 22nd. Finally, Craig Hallum raised their price target on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, March 6th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Bioventus has a consensus rating of “Buy” and an average target price of $14.00.

Bioventus Stock Performance

The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The firm has a market cap of $704.24 million, a P/E ratio of 20.56, a P/E/G ratio of 1.02 and a beta of 0.67. The business’s 50-day simple moving average is $9.65 and its 200 day simple moving average is $8.54.

Bioventus (NASDAQ:BVS) last posted its earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. The business had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, equities analysts predict that Bioventus Inc. will post 0.77 earnings per share for the current year.

Insider Buying and Selling

In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the sale, the director owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. The trade was a 21.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 33.00% of the company’s stock.

Institutional Investors Weigh In On Bioventus

A number of large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its stake in shares of Bioventus by 40.3% during the 1st quarter. Bank of America Corp DE now owns 86,057 shares of the company’s stock worth $786,000 after acquiring an additional 24,723 shares during the last quarter. Engine Capital Management LP purchased a new position in shares of Bioventus during the 1st quarter worth $2,876,000. Quantinno Capital Management LP boosted its stake in shares of Bioventus by 119.6% during the 1st quarter. Quantinno Capital Management LP now owns 72,023 shares of the company’s stock worth $658,000 after acquiring an additional 39,222 shares during the last quarter. Lazard Asset Management LLC boosted its stake in shares of Bioventus by 12.9% during the 1st quarter. Lazard Asset Management LLC now owns 305,517 shares of the company’s stock worth $2,789,000 after acquiring an additional 35,008 shares during the last quarter. Finally, Sei Investments Co. boosted its stake in shares of Bioventus by 160.7% during the 1st quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock worth $2,644,000 after acquiring an additional 178,539 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.